Transthyretin and Amyloid in the Islets of Langerhans in Type-2 Diabetes
2008 (English)In: EXPERIMENTAL DIABETES RESEARCH, ISSN 1687-5214, Vol. 2008, no 429274Article in journal (Refereed) Published
Transthyretin (TTR) is a major amyloid fibril protein in certain systemic forms of amyloidosis. It is a plasma protein, mainly synthesized by the liver but expression occurs also at certain minor locations, including the endocrine cells in the islets of Langerhans. With the use of immunohistochemistry and in situ hybridization, we have studied the distribution of transthyretincontaining cells in islets of Langerhans in type-2 diabetic and nondiabetic individuals. TTR expression was particularly seen in alpha (glucagon) cells. Islets from type-2 diabetic patients had proportionally more transthyretin-reactive islet cells, including beta cells. A weak transthyretin immunoreaction in IAPP-derived amyloid occurred in some specimens. In seeding experiments in vitro, we found that TTR fibrils did not seed IAPP while IAPP fibrils seeded TTR. It is suggested that islet expression of transthyretin may be altered in type-2 diabetes.
Place, publisher, year, edition, pages
2008. Vol. 2008, no 429274
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-19670DOI: 10.1155/2008/429274OAI: oai:DiVA.org:liu-19670DiVA: diva2:227296
Original Publication: Gunilla Westermark and Per Westermark, Transthyretin and Amyloid in the Islets of Langerhans in Type-2 Diabetes, 2008, EXPERIMENTAL DIABETES RESEARCH, (2008), 429274. http://dx.doi.org/10.1155/2008/429274 Copyright: Authors2009-08-282009-07-102014-08-08Bibliographically approved